PINL:GRPOF - Post by User
Comment by
indaknownewfieon Sep 22, 2018 6:42am
211 Views
Post# 28669688
RE:Expect European Pharma partner with Ph. 3 clinical data
RE:Expect European Pharma partner with Ph. 3 clinical dataI agree with everything you are saying Leaf and do not understand why we are not at $2 a share now, I;m long on TBP but Kalytera Therapeutics is about to commence phase 3 too with two different patents involving CBD for treatment of GVHD after organ transplant. They likwise have a CBD/ naproxen subjugate combo in the mix that has advanced too which will be marketed for pain relief in response to opioids.